The Northwest Clinical Community Oncology Program (NW CCOP) has been in existence since the inception of the National Cancer Institute's Clinical Community Oncology Program. As one of the founding CCOPs, the NW CCOP plays an integral role in achieving the National Cancer Institute's (NCI) objective of connecting community cancer specialists and primary care providers with NCI sponsored clinical trials. The NW CCOP is an experienced consortium of hospitals and independent oncology practices spanning three states serving local communities within western Washington, northern Oregon and northern Idaho. The overall purpose of the NW CCOP is to bring clinical advances through the most cutting edge research protocols to local communities. NW CCOP utilizes the Clinical Trials Support Unit (CTSU) as well as the Southwest Oncology Group (SWOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), University of Rochester Cancer Center (URCC), M.D. Anderson Cancer Center (MDACC), and the Sun Coast CCOP Research Bases. The NW CCOP provides community oncologists with the opportunity to participate in a variety of treatment and cancer prevention and control research trials provided by these research bases.
The specific aims of the NW CCOP are to: increase patients'access within Washington, Idaho, and Oregon to advances in treatment and cancer control and prevention clinical trials within their local communities;Expand outreach efforts to minority and underserved populations;Increase the knowledge, awareness, and involvement of the primary healthcare providers to promote increased participation in cancer treatment, and cancer control and prevention trials;and Provide enhanced systems supporting the consortium through communication and training among providers and coordinators thereby promoting quality and timely data collection while maintaining a level of excellence in protection of study participants.
For the past three decades, the NW CCOP has contributed to the body of knowledge and advancements of cancer treatments. The NW CCOP continues to supports the investigation of a variety of chemotherapy agents, from being investigational agents to FDA approved products for a host of indications. Since 1983, we have contributed to significant medical advances especially in the adjuvant treatment settings.
|Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and Oâ¶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62|
|Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8|
|Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42|
|Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7|
|Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
Showing the most recent 10 out of 108 publications